COVERAGE / JNJ / Healthcare

JOHNSON & JOHNSON

Pharmaceutical Preparations

COVERAGE STATUSACTIVE

DATA THROUGH2025-12-28

RESEARCH REPORTS2

SELECTED FILINGS1

Fundamental matrix

Latest / 2025-12-28 · Prior / 2024-12-29 · USD · Annual periods

Revenue

$94.19bn

Prior / $88.82bn

Change / +6.05%

SOURCE / 2026-02-11

Operating income

Not available

Prior / Not available

Change / Unavailable

SOURCE / Not available

Net income

$26.8bn

Prior / $14.07bn

Change / +90.56%

SOURCE / 2026-02-11

Diluted EPS

$11.03

Prior / $5.79

Change / +90.50%

SOURCE / 2026-02-11

Free cash flow

$19.7bn

Prior / $19.84bn

Change / -0.73%

SOURCE / 2026-02-11

Gross margin

67.88%

Prior / 69.07%

Change / -1.19 pp

SOURCE / 2026-02-11

Operating margin

Not available

Prior / Not available

Change / Unavailable

SOURCE / Not available

Return on avg. equity

Not available

Prior / Not available

Change / Unavailable

SOURCE / 2026-02-11

Debt / equity

Not available

Prior / Not available

Change / Unavailable

SOURCE / Not available

ROE uses net income divided by average opening/closing equity. FCF = operating cash flow − selected capital expenditure. Debt/equity is unavailable because a verified interest-bearing-debt series is absent; total liabilities are not substituted for debt.

Inspect source tags, dates and accession numbers

{
  "revenue": {
    "start": "2024-12-30",
    "end": "2025-12-28",
    "val": 94193000000,
    "accn": "0000200406-26-000016",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "frame": "CY2025",
    "tag": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
    "unit": "USD"
  },
  "netIncome": {
    "start": "2024-12-30",
    "end": "2025-12-28",
    "val": 26804000000,
    "accn": "0000200406-26-000016",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "frame": "CY2025",
    "tag": "us-gaap:NetIncomeLoss",
    "unit": "USD"
  },
  "grossProfit": {
    "start": "2024-12-30",
    "end": "2025-12-28",
    "val": 63937000000,
    "accn": "0000200406-26-000016",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "frame": "CY2025",
    "tag": "us-gaap:GrossProfit",
    "unit": "USD"
  },
  "eps": {
    "start": "2024-12-30",
    "end": "2025-12-28",
    "val": 11.03,
    "accn": "0000200406-26-000016",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "frame": "CY2025",
    "tag": "us-gaap:EarningsPerShareDiluted",
    "unit": "USD/shares"
  },
  "operatingCashFlow": {
    "start": "2024-12-30",
    "end": "2025-12-28",
    "val": 24530000000,
    "accn": "0000200406-26-000016",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "frame": "CY2025",
    "tag": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
    "unit": "USD"
  },
  "capex": {
    "start": "2024-12-30",
    "end": "2025-12-28",
    "val": 4832000000,
    "accn": "0000200406-26-000016",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "frame": "CY2025",
    "tag": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment",
    "unit": "USD"
  },
  "totalAssets": {
    "end": "2025-12-28",
    "val": 199210000000,
    "accn": "0000200406-26-000016",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "tag": "us-gaap:Assets",
    "unit": "USD"
  },
  "totalLiabilities": {
    "end": "2025-12-28",
    "val": 117666000000,
    "accn": "0000200406-26-000016",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "tag": "us-gaap:Liabilities",
    "unit": "USD"
  },
  "currentAssets": {
    "end": "2025-12-28",
    "val": 55624000000,
    "accn": "0000200406-26-000016",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "tag": "us-gaap:AssetsCurrent",
    "unit": "USD"
  },
  "currentLiabilities": {
    "end": "2025-12-28",
    "val": 54126000000,
    "accn": "0000200406-26-000016",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "tag": "us-gaap:LiabilitiesCurrent",
    "unit": "USD"
  }
}

Financial trend system

Annual financial trends are summarized in the accessible table below.

Annual figures / accessible table

Period end	Revenue	Net income	Free cash flow	EPS
2025-12-28	$94.19bn	$26.8bn	$19.7bn	$11.03
2024-12-29	$88.82bn	$14.07bn	$19.84bn	$5.79
2023-12-31	$85.16bn	$35.15bn	$18.25bn	$13.72
2023-01-01	$79.99bn	$17.94bn	$17.19bn	$6.73

Valuation context

Historical snapshot / 2026-09-17. Annual accounting period / 2025-12-28. Not current, TTM or forward valuation.

Dated ratios / eligible same-method sector sample
Measure	Snapshot value	Historical median	Sector median	Peer count
P/E	24.50x	Unavailable	27.08x	10
P/S	6.91x	Unavailable	6.63x	10
P/B	Unavailable	Unavailable	7.31x	8
EV / EBITDA	Unavailable	Unavailable	Unavailable	0
FCF yield	3.02%	Unavailable	3.88%	8

Annual denominators, not TTM or forward. Capitalization-based measures use estimated market capitalization from the dated quote snapshot. ADR/share-basis uncertainty is excluded. No comparable historical-multiple series or EV/EBITDA is available. Sector samples are equal-weight medians of this publication’s eligible covered companies; fiscal periods differ. No fair value or price target is implied.

Source: Yahoo Finance completed daily-bar snapshot; not live; market cap estimated using SEC shares at 2026-07-17 DAILY-BAR SOURCE ↗

Retained price snapshot and capitalization estimate

{
  "currentPrice": 270.22,
  "tradingDate": "2026-09-17",
  "marketCap": 651202798881.34,
  "source": "Yahoo Finance completed daily-bar snapshot; not live; market cap estimated using SEC shares at 2026-07-17"
}

Company & operating context

JOHNSON & JOHNSON is an SEC-reporting issuer listed on NYSE under JNJ. Its SEC industry description is Pharmaceutical Preparations. This profile organizes annual financial disclosures for research; sector labels are editorial groupings, not GICS classifications.

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Segment-level revenue is not included in this standardized dataset. Consult the business and segment notes in the linked annual filing for the issuer’s actual reporting segments.

Filing timeline

10-KFILED / 2026-02-11PERIOD / 2025-12-28

JNJ filed this 10-K on 2026-02-11 for the reported period 2025-12-28. Reading focus: Product concentration, research investment, utilization, reimbursement and cash generation. This is a metadata-based reading guide; it does not assert that a particular event or risk change occurred in the document.

ORIGINAL SEC DISCLOSURE ↗

Research archive

HR-0080JNJEarnings Review

JNJ: the annual earnings and cash-flow comparison ↗

JOHNSON & JOHNSON

Research abstract

A two-period review of JNJ revenue, profitability and cash conversion; reported revenue growth was 6.05%.

DATA THROUGH2025-12-282 MIN READPUBLISHED 2026-09-26

HR-0081JNJCompany Research

JNJ: reading the FY2025 financial structure ↗

JOHNSON & JOHNSON

Research abstract

Annual revenue of USD 94.193 billion and net income of USD 26.804 billion for the period ended 2025-12-28.

DATA THROUGH2025-12-282 MIN READPUBLISHED 2026-09-26

Sector context & risk factors

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.

Product concentration, research investment, utilization, reimbursement and cash generation.

HEALTHCARE SYSTEM ↗

Sources & dates

SEC annual filing · 2025-12-28 ↗Source date 2026-02-11
SEC annual filing · 2024-12-29 ↗Source date 2026-02-11
SEC annual filing · 2023-12-31 ↗Source date 2026-02-11
SEC annual filing · 2023-01-01 ↗Source date 2025-02-13
SEC issuer record ↗Source date 2026-09-18